GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Cash Flow from Investing

Mega Genomics (HKSE:06667) Cash Flow from Investing : HK$-12.4 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Jun. 2024, Mega Genomics spent HK$0.7 Mil on purchasing property, plant, equipment. It gained HK$0.0 Mil from selling property, plant, and equipment. It spent HK$0.0 Mil on purchasing business. It gained HK$0.0 Mil from selling business. It spent HK$602.9 Mil on purchasing investments. It gained HK$608.1 Mil from selling investments. It paid HK$0.0Mil for net Intangibles purchase and sale. And it paid HK$0.0 Mil for other investing activities. In all, Mega Genomics gained HK$4.6 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Jun. 2024.


Mega Genomics Cash Flow from Investing Historical Data

The historical data trend for Mega Genomics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Cash Flow from Investing Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
19.66 -36.85 -2.10 -2.86 -36.92

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only -0.07 -2.79 -19.95 -16.97 4.56

Mega Genomics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Mega Genomics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Mega Genomics's Cash Flow from Investing for the quarter that ended in Jun. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-12.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Genomics  (HKSE:06667) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Mega Genomics's purchase of property, plant, equipment for the six months ended in Jun. 2024 was HK$-0.7 Mil. It means Mega Genomics spent HK$0.7 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Mega Genomics's sale of property, plant, equipment for the six months ended in Jun. 2024 was HK$0.0 Mil. It means Mega Genomics gained HK$0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Mega Genomics's purchase of business for the six months ended in Jun. 2024 was HK$0.0 Mil. It means Mega Genomics spent HK$0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Mega Genomics's sale of business for the six months ended in Jun. 2024 was HK$0.0 Mil. It means Mega Genomics gained HK$0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Mega Genomics's purchase of investment for the six months ended in Jun. 2024 was HK$-602.9 Mil. It means Mega Genomics spent {stock_data.stock.currency_symbol}}602.9 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Mega Genomics's sale of investment for the six months ended in Jun. 2024 was HK$608.1 Mil. It means Mega Genomics gained HK$608.1 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Mega Genomics's net Intangibles purchase and sale for the six months ended in Jun. 2024 was HK$-0.0 Mil. It means Mega Genomics paid HK$0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Mega Genomics's cash from discontinued investing activities for the six months ended in Jun. 2024 was 0.0 Mil. It means Mega Genomics paid HK$0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Mega Genomics's cash from other investing activities for the six months ended in Jun. 2024 was HK$-0.0 Mil. It means Mega Genomics paid HK$0.0 Mil for other investing activities.


Mega Genomics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Yu Rong 2501 Other
Guo Meiling 2101 Beneficial owner
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Mei Nian Investment Limited 2101 Beneficial owner
Kastle Limited 2501 Other
Mega Marvelous Limited 2501 Other
Yurong Technology Limited 2101 Beneficial owner
Niu Zhencai 2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Mega Genomics Headlines

No Headlines